# Clinical trial results:
# A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.

## Summary

| | |
|---|---|
| EudraCT number | 2020-001048-24 |
| Trial protocol | IE SK DK DE BE AT LV LT FR NL PL PT IT |
| Global end of trial date | 17 December 2024 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 03 July 2025 |
| First version publication date | 03 July 2025 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | NN7769-4514 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT05053139 |
| WHO universal trial number (UTN) | U1111-1249-4378 |
| Other trial identifiers | Japanese trial registration number: jRCT2031210643 |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Novo Nordisk A/S |
| Sponsor organisation address | Novo Alle, Bagsvaerd, Denmark, 2880 |
| Public contact | Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com |
| Scientific contact | Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMEA-002762-PIP02-20 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 06 February 2024 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 17 December 2024 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To confirm the haemostatic effect of Mim8 as treatment prophylaxis for adult and adolescent patients with haemophilia A with or without inhibitors. This will be done by: - Demonstrating superiority in number of bleeding episodes when treated with Mim8 once-weekly versus no prophylaxis for subjects on no prophylaxis treatment prior to enrolment (Comparing Arm 1 and Arm 2 main treatment period) - Demonstrating non-inferiority in number of bleeding episodes when treated with either Mim8 once-weekly or once-monthly versus treatment with coagulation factor prophylaxis during run-in for subjects on prophylaxis treatment prior to enrolment (Comparing Arm 3 and Arm 4 run-in with main treatment period)

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki (Oct 2013) and ICH Good Clinical Practice, including archiving of essential documents (May 1996) and EN ISO 14155 Part 1 and 2 and FDA 21 CFR 312.120.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 02 December 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Austria: 5 |
| Country: Number of subjects enrolled | Belgium: 3 |
| Country: Number of subjects enrolled | Canada: 3 |
| Country: Number of subjects enrolled | Switzerland: 6 |
| Country: Number of subjects enrolled | China: 36 |
| Country: Number of subjects enrolled | Germany: 16 |
| Country: Number of subjects enrolled | Denmark: 6 |
| Country: Number of subjects enrolled | Spain: 6 |
| Country: Number of subjects enrolled | France: 10 |
| Country: Number of subjects enrolled | United Kingdom: 15 |
| Country: Number of subjects enrolled | India: 12 |
| Country: Number of subjects enrolled | Ireland: 1 |
| Country: Number of subjects enrolled | Israel: 4 |
| Country: Number of subjects enrolled | Italy: 9 |
| Country: Number of subjects enrolled | Japan: 12 |
| Country: Number of subjects enrolled | Korea, Republic of: 18 |

| | |
|---|---|
| Country: Number of subjects enrolled | Lithuania: 5 |
| Country: Number of subjects enrolled | Latvia: 3 |
| Country: Number of subjects enrolled | Mexico: 2 |
| Country: Number of subjects enrolled | Malaysia: 6 |
| Country: Number of subjects enrolled | Netherlands: 9 |
| Country: Number of subjects enrolled | Poland: 25 |
| Country: Number of subjects enrolled | Portugal: 7 |
| Country: Number of subjects enrolled | Romania: 5 |
| Country: Number of subjects enrolled | Russian Federation: 3 |
| Country: Number of subjects enrolled | Saudi Arabia: 7 |
| Country: Number of subjects enrolled | Serbia: 2 |
| Country: Number of subjects enrolled | Slovakia: 4 |
| Country: Number of subjects enrolled | Türkiye: 11 |
| Country: Number of subjects enrolled | Taiwan: 4 |
| Country: Number of subjects enrolled | United States: 20 |
| Country: Number of subjects enrolled | South Africa: 6 |
| Worldwide total number of subjects | 281 |
| EEA total number of subjects | 114 |

Notes:

| **Subjects enrolled per age group** | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 87 |
| Adults (18-64 years) | 190 |
| From 65 to 84 years | 4 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 100 sites that enrolled subjects in 32 countries. The study was conducted in 2 parts: main part (26 weeks) and extension part (26 weeks), With 5 randomized arms (Arm 1, 2a, 2b, 3 and 4).

### Pre-assignment

Screening details:

Subjects on coagulation factor prophylaxis entered run-in period (26 weeks) in Arm 3 and 4 to collect high-quality bleeding, treatment data and randomized to main part. Subjects with no prophylaxis (Arm 1, 2a and 2b) was randomized to main part directly. After main part of study, subjects continued in the extension part of the study.

### Period 1

| | |
|---|---|
| Period 1 title | Main Phase (26 weeks) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Arm1: No PPX - Mim8 PPX QW/QM |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly or once monthly in Arm 1 during extension phase as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing.

| | |
|---|---|
| **Arm title** | Arm 2a: Mim8 PPX QW |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly dose in Arm 2a as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| | |
|---|---|
| **Arm title** | Arm 2b: Mim8 PPX QM |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once monthly dose in Arm 2b as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| | |
|---|---|
| **Arm title** | Arm 3: PPX - Mim8 PPX QW |

Arm description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly dose in Arm 3 as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| | |
|---|---|
| **Arm title** | Arm 4: PPX- Mim8 PPX QM |

Arm description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once monthly dose in Arm 4 as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| **Number of subjects in period 1** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM |
|---|---|---|---|
| Started | 18 | 22 | 21 |
| Completed | 18 | 21 | 21 |
| Not completed | 0 | 1 | 0 |
| Physician decision | - | 1 | - |
| Consent withdrawn by subject | - | - | - |
| Withdrawal by Parent/Guardian | - | - | - |

| **Number of subjects in period 1** | Arm 3: PPX - Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|
| Started | 111 | 109 |
| Completed | 105 | 108 |
| Not completed | 6 | 1 |
| Physician decision | 2 | 1 |
| Consent withdrawn by subject | 3 | - |
| Withdrawal by Parent/Guardian | 1 | - |

## Period 2

| | |
|---|---|
| Period 2 title | Extension Phase (26 weeks) |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Arm1: No PPX - Mim8 PPX QW/QM |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on

agreement with the investigator.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly or once monthly in Arm 1 during extension phase as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing.

| | |
|---|---|
| **Arm title** | Arm 2a: Mim8 PPX QW |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly or once monthly in Arm 2a as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing.

| | |
|---|---|
| **Arm title** | Arm 2b: Mim8 PPX QM |

Arm description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once-monthly dose in Arms 2b as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| | |
|---|---|
| **Arm title** | Arm 3: PPX - Mim8 PPX QW |

Arm description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once weekly dose in Arm 3 as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| | |
|---|---|
| **Arm title** | Arm 4: PPX- Mim8 PPX QM |

Arm description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | NNC0365-3769 B (Mim8) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

A loading dose was administered once, followed by once monthly dose in Arm 4 as maintenance doses. Dose amount is based on weight band of subject, whether it is a loading or maintenance dose, and the frequency of dosing

| **Number of subjects in period 2[1]** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM |
|---|---|---|---|
| Started | 18 | 21 | 21 |
| Arm 1: Mim8 QW | 8 [2] | 0 [3] | 0 [4] |
| Arm1: Mim8 QM | 10 [5] | 0 [6] | 0 [7] |
| Completed | 17 | 21 | 21 |
| Not completed | 1 | 0 | 0 |
| Consent withdrawn by subject | 1 | - | - |
| Physician decision | - | - | - |

| **Number of subjects in period 2[1]** | Arm 3: PPX - Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|
| Started | 104 | 108 |
| Arm 1: Mim8 QW | 0 [8] | 0 [9] |
| Arm1: Mim8 QM | 0 [10] | 0 [11] |
| Completed | 104 | 106 |
| Not completed | 0 | 2 |
| Consent withdrawn by subject | - | 1 |
| Physician decision | - | 1 |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: As per the data this is correct, this is a bug thrown by PharmaCM

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[9] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[10] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

[11] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: Arm 1: Mim8 QW: The milestone is only applicable for Arm 1 (QW)

## Baseline characteristics

### Reporting groups

| Reporting group title | Arm1: No PPX - Mim8 PPX QW/QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| Reporting group title | Arm 2a: Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 2b: Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 3: PPX - Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 4: PPX- Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM |
|---|---|---|---|
| Number of subjects | 18 | 22 | 21 |
| Age Categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 6 | 6 | 5 |
| Adults (18-64 years) | 12 | 16 | 16 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 30 | 31 | 33 |
| standard deviation | ± 13 | ± 16 | ± 16 |
| Gender Categorical | | | |
| Units: Subjects | | | |
| Female | 1 | 0 | 2 |
| Male | 17 | 22 | 19 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 12 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 4 | 9 | 7 |
| More than one race | 1 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 1 | 2 |
| Not Hispanic or Latino | 17 | 21 | 19 |
| Unknown or Not Reported | 1 | 0 | 0 |

| **Reporting group values** | Arm 3: PPX - Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM | Total |
|---|---|---|---|
| Number of subjects | 111 | 109 | 281 |
| Age Categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 37 | 33 | 87 |
| Adults (18-64 years) | 73 | 73 | 190 |
| From 65-84 years | 1 | 3 | 4 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 31 | 31 | |
| standard deviation | ± 16 | ± 16 | - |

| Gender Categorical<br>Units: Subjects | | | |
|---|---|---|---|
| Female | 0 | 1 | 4 |
| Male | 111 | 108 | 277 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 25 | 28 | 89 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 7 |
| White | 72 | 68 | 160 |
| More than one race | 7 | 7 | 15 |
| Unknown or Not Reported | 5 | 4 | 9 |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 2 | 2 | 7 |
| Not Hispanic or Latino | 104 | 103 | 264 |
| Unknown or Not Reported | 5 | 4 | 10 |

### End points reporting groups

| Reporting group title | Arm1: No PPX - Mim8 PPX QW/QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| Reporting group title | Arm 2a: Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 2b: Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 3: PPX - Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 4: PPX- Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm1: No PPX - Mim8 PPX QW/QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| Reporting group title | Arm 2a: Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 2b: Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 3: PPX - Mim8 PPX QW |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Reporting group title | Arm 4: PPX- Mim8 PPX QM |
|---|---|

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Subject analysis set title | Arm1: No PPX - Mim8 PPX QW/QM |
|---|---|
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| Subject analysis set title | Arm 2a: Mim8 PPX QW |
|---|---|
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Subject analysis set title | Arm 2b: Mim8 PPX QM |
|---|---|
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Subject analysis set title | Arm 3: PPX - Mim8 PPX QW (Run-in Part) |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Subject analysis set title | Arm 3: PPX - Mim8 PPX QW (Main Part) |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks. Subjects entered the main part of the study, to receive loading dose of 24 mg (body weight 30-<45 kg) to 55 mg (body weight >=45 kg) Mim8 QW followed by maintenance dose of 4 mg (body weight 30 -<45 kg)-9 mg >=45 kg) subcutaneously. After the main part, subjects continued to receive the same dosing schedule of Mim8 QW subcutaneously in the extension part of the study (26 weeks).

| | |
|---|---|
| Subject analysis set title | Arm 4: PPX- Mim8 PPX QM (Run-in Part) |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Subject analysis set title | Arm 4: PPX- Mim8 PPX QM (Main Part) |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Subject analysis set title | Arm 2a: Mim8 PPX QW |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of 24 mg (body weight 30-<45 kg) to 55 mg (body weight >=45 kg) Mim8 QW followed by maintenance dose of 4 mg (body weight 30 -<45 kg)-9 mg (body weight >=45 kg) subcutaneously. After the main part, subjects continued to receive the same dosing schedule of Mim8 QW subcutaneously in the extension part of the study (26 weeks).

| | |
|---|---|
| Subject analysis set title | Arm 2b: Mim8 PPX QM |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of 40 mg (body weight 30-<45 kg)-92 mg (body weight ≥45 kg) Mim8 QM followed by maintenance dose 20 mg (body weight 30-<45 kg)-46 mg (body weight >=45 kg) subcutaneously. After the main part, subjects continued to receive the same dosing schedule of Mim8 QM subcutaneously in the extension part of the study (26 weeks).

| | |
|---|---|
| Subject analysis set title | Arm 3: PPX - Mim8 PPX QW |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks. Subjects entered the main part of the study, to receive loading dose of 24 mg (body weight 30-<45 kg) to 55 mg (body weight >=45 kg) Mim8 QW

followed by maintenance dose of 4 mg (body weight 30 -<45 kg)-9 mg >=45 kg) subcutaneously. After the main part, subjects continued to receive the same dosing schedule of Mim8 QW subcutaneously in the extension part of the study (26 weeks).

| | |
|---|---|
| Subject analysis set title | Arm 4: PPX- Mim8 PPX QM |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks. Subjects entered main part of the study, to receive loading dose of 40 mg (body weight 30-<45 kg)-92 mg (body weight ≥45 kg) Mim8 QM followed by maintenance dose 20 mg (body weight 30-<45 kg)-46 mg (body weight >=45 kg) subcutaneously. After the main part, subjects continued to receive the same dosing schedule of Mim8 QM subcutaneously in the extension part of the study (26 weeks).

## Primary: No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated bleeds (Annualised Bleeding Rate)

| | |
|---|---|
| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated bleeds (Annualised Bleeding Rate) |

End point description:

Number of treated bleeds per year (Annualised Bleeding Rate) data is reported. Annualised bleeding rate (ABR) is the number of bleeding episodes per year. Full analysis set (FAS) population included all subjects randomized.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

From randomisation (week 0) to end of main part (Week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 21 | 20 | |
| Units: Bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 15.75 (10.70 to 23.20) | 0.45 (0.18 to 1.14) | 0.20 (0.06 to 0.72) | |

### Statistical analyses

| Statistical analysis title | No PPX Vs Mim8 PPX QM |
|---|---|
| Comparison groups | Arm1: No PPX - Mim8 PPX QW/QM v Arm 2b: Mim8 PPX QM |
| Number of subjects included in analysis | 37 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | Negative Binomial Regression |
| Parameter estimate | Annualised bleeding rate ratio |
| Point estimate | 0.013 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.003 |
| upper limit | 0.048 |

| **Statistical analysis title** | No PPX Vs Mim8 PPX QW |
|---|---|
| Comparison groups | Arm1: No PPX - Mim8 PPX QW/QM v Arm 2a: Mim8 PPX QW |
| Number of subjects included in analysis | 38 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | Negative binomial regression |
| Parameter estimate | Annualised bleeding rate ratio |
| Point estimate | 0.029 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.011 |
| upper limit | 0.078 |

**Primary: Prophylaxis treatment (Arms 3 and 4): Number of treated bleeds (Annualised Bleeding Rate)**

| End point title | Prophylaxis treatment (Arms 3 and 4): Number of treated bleeds (Annualised Bleeding Rate) |
|---|---|

End point description:

Number of treated bleeds per year (Annualised Bleeding Rate) data is reported. Annualised bleeding rate(ABR) is the number of bleeding episodes per year. Full analysis set (FAS) population included all participants randomised

| End point type | Primary |
|---|---|

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)

| **End point values** | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 4.83 (3.59 to 6.51) | 2.51 (1.42 to 4.42) | 3.10 (2.23 to 4.29) | 1.78 (1.17 to 2.71) |

**Statistical analyses**

| **Statistical analysis title** | PPX (run-in) vs Mim8 PPX QM (main) |
|---|---|

Statistical analysis description:

The actual analyzed population is 98 subjects

| Comparison groups | Arm 4: PPX- Mim8 PPX QM (Run-in Part) v Arm 4: PPX- Mim8 |
|---|---|

| | PPX QM (Main Part) |
|---|---|
| Number of subjects included in analysis | 196 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0066 |
| Method | Negative binomial regression |
| Parameter estimate | Annualised bleeding rate ratio |
| Point estimate | 0.574 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.385 |
| upper limit | 0.857 |

| **Statistical analysis title** | PPX (Run-in) vs Mim8 PPX QW (Main) |
|---|---|
| Statistical analysis description: | |
| The actual analyzed population is 98 subjects | |
| Comparison groups | Arm 3: PPX - Mim8 PPX QW (Run-in Part) v Arm 3: PPX - Mim8 PPX QW (Main Part) |
| Number of subjects included in analysis | 196 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0406 |
| Method | Negative binomial regression |
| Parameter estimate | Annualised bleeding rate ratio |
| Point estimate | 0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.278 |
| upper limit | 0.973 |

| **Secondary: Arms 2a, 2b, 3 and 4: Number of injection site reactions** | |
|---|---|
| End point title | Arms 2a, 2b, 3 and 4: Number of injection site reactions |
| End point description: | |
| Number of injection site reactions data is reported from randomisation (week 0) to end of main (week 26). Full analysis set (FAS) population included all subjects randomized. | |
| End point type | Secondary |
| End point timeframe: | |
| From randomisation (week 0) to end of main (week 26) | |

| End point values | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 21 | 20 | 98 | 98 |
| Units: Number of events | | | | |
| number (not applicable) | 2 | 2 | 86 | 13 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Prophylaxis treatment (Arms 3 and 4): Number of treated spontaneous bleeds

| End point title | Prophylaxis treatment (Arms 3 and 4): Number of treated spontaneous bleeds |
|---|---|

End point description:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26). Full analysis set (FAS) population included all subjects randomised

| End point type | Secondary |
|---|---|

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)

| End point values | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Spontaneous bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 2.73 (1.94 to 3.86) | 1.49 (0.65 to 3.42) | 1.83 (1.10 to 3.04) | 0.74 (0.42 to 1.32) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Arms 2a, 2b, 3 and 4: Number of participants with anti-Mim8 antibodies

| End point title | Arms 2a, 2b, 3 and 4: Number of participants with anti-Mim8 antibodies |
|---|---|

End point description:

Number of participants with anti-Mim8 antibodies from randomisation (week 0) to end of extension (week 52) is reported. Safety analysis set (SAS) included all subjects randomly assigned to study treatment and who take at least 1 dose of study product.

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of extension (week 52)

| End point values | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 22 | 21 | 111 | 109 |
| Units: Subjects | 2 | 2 | 12 | 5 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated spontaneous bleeds (Annualised Bleeding Rate)

| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated spontaneous bleeds (Annualised Bleeding Rate) |
|---|---|

End point description:

Number of treated spontaneous bleeds per year (ABR) data is reported from randomisation (week 0) to end of main (week 26). ABR is the number of bleeding episodes per year. Full analysis set (FAS) population included all subjects randomised

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of main (Week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 21 | 20 | |
| Units: Spontaneous bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 11.78 (7.48 to 18.54) | 0.09 (0.01 to 0.69) | 0.24 (0.07 to 0.85) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Prophylaxis treatment (Arms 3 and 4): Number of treated joint bleeds

| End point title | Prophylaxis treatment (Arms 3 and 4): Number of treated joint bleeds |
|---|---|

End point description:

Number of treated joint bleeds data is reported from initiation of run-in (26-52 weeks prior to week 0) to week 0. Full analysis set (FAS) included all subjects randomized.

| End point type | Secondary |
|---|---|

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomization (week 0) to end of main (Week 26)

| **End point values** | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Spontaneous bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 3.60 (2.62 to 4.95) | 1.80 (0.91 to 3.55) | 2.06 (1.43 to 2.97) | 1.09 (0.60 to 1.99) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated joint bleeds

| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated joint bleeds |
|---|---|

End point description:

Number of treated joint bleeds data is reported from randomisation (week 0) to end of main (Week 26)

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of main (Week 26)

| **End point values** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 21 | 20[1] | |
| Units: Joint bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 10.60 (6.28 to 17.89) | 0.48 (0.18 to 1.29) | 99999 (99999 to 99999) | |

Notes:

[1] - Since number of subjects with bleeding is zero, mean and 95% CI data is not available.

## Statistical analyses

No statistical analyses for this end point

## Secondary: No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated traumatic bleeds

| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Number of |
|---|---|

| | |
|---|---|
| | treated traumatic bleeds |

End point description:

Number of treated traumatic bleeds data is reported from randomisation (week 0) to end of main (Week 26)

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

From randomisation (week 0) to end of main (Week 26)

| **End point values** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 20 | 21 | |
| Units: Traumatic bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 1.86 (0.86 to 4.05) | 0.19 (0.05 to 0.67) | 99999 (99999 to 99999) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Prophylaxis treatment (Arms 3 and 4): Number of treated traumatic bleeds

| | |
|---|---|
| End point title | Prophylaxis treatment (Arms 3 and 4): Number of treated traumatic bleeds |

End point description:

Number of treated traumatic bleeds data is reported From initiation of run-in (26-52 weeks prior to week 0) to week 0

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomization (week 0) to end of main (Week 26)

| **End point values** | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Traumatic bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 1.95 (1.39 to 2.74) | 0.89 (0.58 to 1.37) | 1.28 (0.94 to 1.75) | 0.88 (0.57 to 1.37) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Prophylaxis treatment (Arms 3 and 4): Number of treated target joint bleeds

| End point title | Prophylaxis treatment (Arms 3 and 4): Number of treated target joint bleeds |
|---|---|

End point description:

Number of treated target joint bleeds data is reported From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)

| End point type | Secondary |
|---|---|

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)

| End point values | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Spontaneous bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 1.12 (0.62 to 2.02) | 0.38 (0.14 to 1.08) | 0.48 (0.21 to 1.09) | 0.35 (0.11 to 1.08) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated target joint bleeds

| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Number of treated target joint bleeds |
|---|---|

End point description:

Number of treated target joint bleeds data is reported from randomisation (week 0) to end of main (Week 26)

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of main (Week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 21 | 20 | |
| Units: Spontaneous bleeding episodes per year | | | | |
| arithmetic mean (confidence interval 95%) | 3.91 (1.96 to 7.77) | 0.26 (0.07 to 0.99) | 99999 (99999 to 99999) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: (Arms 2a, 2b, 3 and 4): Mim8 plasma concentration

| End point title | (Arms 2a, 2b, 3 and 4): Mim8 plasma concentration |
|---|---|

End point description:

Mim8 plasma concentration data is presented from randomisation (week 0) to end of extension (week 52) in this endpoint. Data is reported in which subjects were a part of at any time from week 0 to week 52, not at specific time points assessed from week 0 to week 52. FAS included all subjects who were randomized

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of extension (week 52)

| End point values | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 22 | 21 | 109 | 108 |
| Units: microgram per mililiter (µg/mL) | | | | |
| arithmetic mean (standard deviation) | 4.93 (± 1.96) | 3.50 (± 1.42) | 4.81 (± 1.65) | 4.18 (± 1.76) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Prophylaxis treatment (Arms 3 and 4): Consumption of factor product per bleed treatment (number of injections)

| End point title | Prophylaxis treatment (Arms 3 and 4): Consumption of factor product per bleed treatment (number of injections) |
|---|---|

End point description:

Number of injections consumed per bleed treatment data is reported from initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26). FAS included all subjects who were randomised.

| End point type | Secondary |
|---|---|

End point timeframe:

From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26).

| End point values | Arm 3: PPX - Mim8 PPX QW (Run-in Part) | Arm 3: PPX - Mim8 PPX QW (Main Part) | Arm 4: PPX- Mim8 PPX QM (Run-in Part) | Arm 4: PPX- Mim8 PPX QM (Main Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 98 | 98 | 98 | 98 |
| Units: Number of injections | | | | |
| arithmetic mean (standard deviation) | 1.8 (± 2.6) | 1.8 (± 1.6) | 1.4 (± 1.0) | 1.5 (± 1.2) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: No prophylaxis treatment (Arms 1, 2a, and 2b): Consumption of factor product per bleed treatment (number of injections)

| End point title | No prophylaxis treatment (Arms 1, 2a, and 2b): Consumption of factor product per bleed treatment (number of injections) |
|---|---|

End point description:

Consumption of factor product per bleed treatment (number of injections) is reported from randomisation (week 0) to end of main (Week 26). Full analysis set (FAS) included all subjects who were randomised.

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to end of main (Week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 17 | 21 | 20 | |
| Units: Number of injections | | | | |
| arithmetic mean (standard deviation) | 1.7 (± 1.9) | 1.2 (± 0.4) | 1.0 (± 0.0) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: All participants (Arms 1, 2a, 2b, 3 and 4): Change in physical function domain of PedsQLTM

| End point title | All participants (Arms 1, 2a, 2b, 3 and 4): Change in physical function domain of PedsQLTM |
|---|---|

End point description:

PedsQL measures quality of life and the physical functioning domain measures physical functioning. Higher scores indicate a better quality of life and better physical functioning. Positive change indicates

improvement and negative change indicates worsening. The score ranges from 0-100. FAS included all subjects who were randomised. Here, overall number of subjects analysed (N) = subjects with available data for this outcome measure.

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to the end of the main part (week 26)

| **End point values** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW (Run-in Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 12 | 13 | 15 | 79 |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | -5.5 (± 17.8) | 14.2 (± 22.0) | 20.8 (± 20.3) | 1.9 (± 13.1) |

| **End point values** | Arm 4: PPX-Mim8 PPX QM (Run-in Part) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 81 | | | |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | 2.1 (± 10.1) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Arms 1, 2a, 2b, 3 and 4: Change in participant’s treatment burden using the Hemo-TEM

| End point title | Arms 1, 2a, 2b, 3 and 4: Change in participant’s treatment burden using the Hemo-TEM |
|---|---|

End point description:

Hemophilia Treatment Experience Measure (Hemo -TEM) measures treatment burden. Higher scores indicate a greater treatment burden and negative change indicates improvement. The score ranges from 0-100. FAS included all subjects who were randomised. Here, Overall number of subjects analysed (N) = subjects with available data for this outcome measure.

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to the end of the main part (week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW (Run-in Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 12 | 13 | 15 | 82 |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | -2.2 (± 14.1) | -9.9 (± 13.4) | -11.2 (± 11.6) | -10.8 (± 15.5) |

| End point values | Arm 4: PPX-Mim8 PPX QM (Run-in Part) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 85 | | | |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | -10.0 (± 10.5) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Arms 1, 2a, 2b, 3 and 4: Change in participant’s joint pain score using Joint Pain Rating Scale (JPRS)

| End point title | Arms 1, 2a, 2b, 3 and 4: Change in participant’s joint pain score using Joint Pain Rating Scale (JPRS) |
|---|---|

End point description:

JPRS measures joint pain. Higher scores indicate a higher joint pain intensity. The questionnaire asks "In the past 7 days, how would you rate your worst pain in your joints?". Positive change indicates improvement and negative change indicates worsening. The score ranges from 0-10. FAS included all subjects who were randomised. Here, Overall number of subjects analysed (N) = subjects with available data for this outcome measure.

| End point type | Secondary |
|---|---|

End point timeframe:

From randomisation (week 0) to the end of the main part (week 26)

| End point values | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 2b: Mim8 PPX QM | Arm 3: PPX - Mim8 PPX QW (Run-in Part) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 12 | 13 | 15 | 82 |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | -0.8 (± 2.4) | -0.5 (± 3.4) | -1.8 (± 2.8) | -0.1 (± 2.4) |

| End point values | Arm 4: PPX-Mim8 PPX QM (Run-in Part) | | | |
|---|---|---|---|---|

| Subject group type | Subject analysis set | | | |
|---|---|---|---|---|
| Number of subjects analysed | 85 | | | |
| Units: Score points | | | | |
| arithmetic mean (standard deviation) | -0.3 (± 1.9) | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From randomisation (week 0) to end of the trial (Week 52)

Adverse event reporting additional description:

The data presented for Arm1 includes both the main period (No PPX) and the extension period (Mim8 PPX QW/QM)

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 27 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Arm1: No PPX - Mim8 PPX QW/QM |

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and continued no prophylaxis (on-demand treatment with their standard of care products) treatment in the main part of the study (26 weeks). After the main part, subjects continued in the extension part of the study (26 weeks) to receive either once-weekly (QW) loading dose of 24 milligram (mg) (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 4 mg (body weight 30-<45 kg) or 9 mg (body weight >=45 kg) respectively, or once-monthly (QM) loading dose of 40 mg (body weight 30-<45 kg) or 92 mg (body weight >=45 kg) Mim8 subcutaneously followed by maintenance dose of 20 mg (body weight 30 - <45 kg) or 46 mg (body weight >=45 kg) respectively, based on agreement with the investigator.

| | |
|---|---|
| Reporting group title | Arm 2a: Mim8 PPX QW |

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Reporting group title | Arm 4: PPX- Mim8 PPX QM |

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered main part of the study, to receive loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Reporting group title | Arm 3: PPX - Mim8 PPX QW |

Reporting group description:

Subjects on coagulation factor prophylaxis prior to enrolment continued with the same product type and dosing frequency in the run-in period for at least 26 weeks and up to 52 weeks. Subjects entered the main part of the study, to receive loading dose of either 24 mg (body weight 30-<45 kg) or 55 mg (body weight >=45 kg) Mim8 QW subcutaneously followed by maintenance dose of 4 mg (body weight 30 -<45 kg) or 9 mg >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QW subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| | |
|---|---|
| Reporting group title | Arm 2b: Mim8 PPX QM |

Reporting group description:

Subjects on no prophylaxis treatment did not enter the run-in period and received loading dose of wither 40 mg (body weight 30-<45 kg) or 92 mg (body weight ≥45 kg) Mim8 QM subcutaneously followed by maintenance dose of 20 mg (body weight 30-<45 kg) or 46 mg (body weight >=45 kg) respectively. After the main part, subjects continued to receive the same dosing regimen of Mim8 QM subcutaneously in the extension part of the study (26 weeks). The dose could only be changed in relation to weight band change.

| Serious adverse events | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 22 (4.55%) | 9 / 109 (8.26%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Testicular teratoma benign | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Head injury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ligament sprain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Epilepsy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| VIth nerve paralysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 22 (4.55%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthropathy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma muscle | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Synovitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psoas abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 22 (4.55%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Soft tissue infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |

| | | | |
|---|---|---|---|
| Device loosening | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Arm 3: PPX - Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 111 (6.31%) | 0 / 21 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Testicular teratoma benign | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Head injury | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ligament sprain | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb injury | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Epilepsy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VIth nerve paralysis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthropathy | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma muscle | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Synovitis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal abscess | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psoas abscess | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Soft tissue infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Product issues | | | |
| Device loosening | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Arm1: No PPX - Mim8 PPX QW/QM | Arm 2a: Mim8 PPX QW | Arm 4: PPX- Mim8 PPX QM |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 10 / 18 (55.56%) | 9 / 22 (40.91%) | 62 / 109 (56.88%) |
| Investigations | | | |
| Prothrombin fragment 1.2 increased | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 2 / 22 (9.09%) | 9 / 109 (8.26%) |
| occurrences (all) | 2 | 2 | 9 |
| Surgical and medical procedures | | | |
| Intra-uterine contraceptive device removal | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 22 (4.55%) | 9 / 109 (8.26%) |
| occurrences (all) | 1 | 1 | 16 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |
| General disorders and administration site conditions | | | |

| | | | |
|---|---|---|---|
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 22 (9.09%) | 3 / 109 (2.75%) |
| occurrences (all) | 0 | 2 | 3 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 1 / 22 (4.55%) | 5 / 109 (4.59%) |
| occurrences (all) | 2 | 1 | 6 |
| Injection site erythema | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 2 / 109 (1.83%) |
| occurrences (all) | 1 | 0 | 2 |
| Gastrointestinal disorders | | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 4 / 109 (3.67%) |
| occurrences (all) | 1 | 0 | 4 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastritis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 3 / 109 (2.75%) |
| occurrences (all) | 0 | 0 | 3 |
| Skin and subcutaneous tissue disorders | | | |
| Umbilical erythema | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 22 (4.55%) | 10 / 109 (9.17%) |
| occurrences (all) | 0 | 1 | 15 |
| Back pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 22 (4.55%) | 7 / 109 (6.42%) |
| occurrences (all) | 1 | 1 | 7 |
| Sacroiliitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| Influenza | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 22 (4.55%) | 5 / 109 (4.59%) |
| occurrences (all) | 0 | 1 | 6 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 22 (9.09%) | 0 / 109 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 22 (9.09%) | 17 / 109 (15.60%) |
| occurrences (all) | 2 | 6 | 20 |
| Body tinea | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| COVID-19 | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 22 (4.55%) | 9 / 109 (8.26%) |
| occurrences (all) | 0 | 1 | 9 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 22 (0.00%) | 16 / 109 (14.68%) |
| occurrences (all) | 0 | 0 | 23 |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 22 (0.00%) | 0 / 109 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 22 (0.00%) | 1 / 109 (0.92%) |
| occurrences (all) | 1 | 0 | 1 |

| **Non-serious adverse events** | Arm 3: PPX - Mim8 PPX QW | Arm 2b: Mim8 PPX QM | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 60 / 111 (54.05%) | 6 / 21 (28.57%) | |
| Investigations | | | |
| Prothrombin fragment 1.2 increased | | | |
| subjects affected / exposed | 14 / 111 (12.61%) | 1 / 21 (4.76%) | |
| occurrences (all) | 15 | 1 | |
| Surgical and medical procedures | | | |
| Intra-uterine contraceptive device removal | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 12 / 111 (10.81%) | 1 / 21 (4.76%) | |
| occurrences (all) | 15 | 1 | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| General disorders and administration site conditions | | | |

| | | | |
|---|---|---|---|
| Injection site reaction | | | |
| subjects affected / exposed | 7 / 111 (6.31%) | 1 / 21 (4.76%) | |
| occurrences (all) | 103 | 2 | |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 111 (2.70%) | 2 / 21 (9.52%) | |
| occurrences (all) | 3 | 2 | |
| Injection site erythema | | | |
| subjects affected / exposed | 3 / 111 (2.70%) | 0 / 21 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 5 / 111 (4.50%) | 1 / 21 (4.76%) | |
| occurrences (all) | 8 | 1 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dyspepsia | | | |
| subjects affected / exposed | 3 / 111 (2.70%) | 2 / 21 (9.52%) | |
| occurrences (all) | 4 | 2 | |
| Gastritis | | | |
| subjects affected / exposed | 2 / 111 (1.80%) | 1 / 21 (4.76%) | |
| occurrences (all) | 2 | 1 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 6 / 111 (5.41%) | 1 / 21 (4.76%) | |
| occurrences (all) | 6 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Umbilical erythema | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|---|---|---|
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 6 / 111 (5.41%) | 0 / 21 (0.00%) | |
| occurrences (all) | 6 | 0 | |
| Back pain | | | |
| subjects affected / exposed | 6 / 111 (5.41%) | 0 / 21 (0.00%) | |
| occurrences (all) | 6 | 0 | |
| Sacroiliitis | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| Influenza | | | |
| subjects affected / exposed | 6 / 111 (5.41%) | 0 / 21 (0.00%) | |
| occurrences (all) | 8 | 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 2 / 111 (1.80%) | 0 / 21 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 11 / 111 (9.91%) | 3 / 21 (14.29%) | |
| occurrences (all) | 18 | 4 | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 111 (0.00%) | 0 / 21 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 7 / 111 (6.31%) | 0 / 21 (0.00%) | |
| occurrences (all) | 7 | 0 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 11 / 111 (9.91%) | 0 / 21 (0.00%) | |
| occurrences (all) | 16 | 0 | |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | 0 / 21 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Urinary tract infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed<br>occurrences (all) | 0 / 111 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | |
| Metabolism and nutrition disorders<br>Hyperuricaemia<br>subjects affected / exposed<br>occurrences (all)<br>Hypokalaemia<br>subjects affected / exposed<br>occurrences (all)<br>Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all) | <br><br>0 / 111 (0.00%)<br>0<br><br>0 / 111 (0.00%)<br>0<br><br>1 / 111 (0.90%)<br>1 | <br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0 | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 08 October 2021 | Protocol version 5.0: Change of treatment prophylaxis to bleeding prophylaxis in the primary objective and remove subjects in the sentence; Bleeds into target joints must be treated or prescribed treatment to be a target joint bleed; The run-in period is planned to be of up to 52 weeks duration; Participants on no prophylaxis are not allowed to participate in the run-in; In total approximately 244 participants are planned to be enrolled into this study, with at least 30 adolescent (12-17 years) participants; Patients on coagulation factor prophylaxis will preferably continue the same product type; Changed that on-demand treatment will receive Standard of Care product instead of usual product. |
| 22 November 2022 | Protocol version 9.0: A new study design for participants who are on no prophylaxis/on-demand treatment prior to enrolment and a change of primary endpoint analyses for Mim8 QW and QM in treatment Arms 3 and 4 were also included based on authority feedback; Primary endpoint analyses for Mim8 QW and QM treatment arms will be performed separately in a hierarchical manner. Superiority test will be performed for Arms 3 and 4 without a non-inferiority test; The total number of participants has been updated to 267; Exclusion criterion updated regarding requirement of participation in any interventional clinical study prior to this study, regarding exposure to nonfactor haemostatic products and regarding timing of planned major surgery; In the estimand section the handling of intercurrent events has been elaborated and 'major surgery' has been removed as an intercurrent event. |
| 29 September 2023 | Protocol version 11.0: Reintroduced non-inferiority tests for Arms 3 and 4 as the first step in the statistical testing hierarchy followed by the superiority tests. The power calculation based on non inferiority and superiority are provided; Added an additional secondary endpoint related to Mim8 plasma concentration addressing health authority feedback; Extended the visit window for Visit 13 for countries and sites where participants' transfer to study NN7769-4532 is not possible either due to study not being approved or sites not being open for transfer at the time of visit; Included country-specific requirements for EU countries, United States and Russia. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported